MPTP


Also found in: Acronyms, Wikipedia.

MPTP

Piperidine derivative that causes irreversible symptoms of parkinsonism in humans and monkeys. A by-product of illicitly manufactured meperidine that caused numerous cases of parkinsonism. Used as an experimental tool in research on parkinsonism.

MPTP

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, analogs MTMP, PEPAP Neurology A potent neurotoxin–which has an effect much like Meperidine or Demerol—that acts on neuromelanin, producing parkinsonism Clinical Bradykinesia, muscular rigidity, resting tremor, defects of posture and gait Pharmacologic effects MPTP initially blocks the brain's responses to pain, then metabolizes to MPP+, causing an irreversible syndrome resembling Parkinson's disease. See BDNF, Designer drugs, Parkinson's disease.
References in periodicals archive ?
The investigators propose that once MPTP is converted to MPP.
Bakay and his colleagues administered MPTP to rhesus monkeys.
STAT3 is now known to be present in cardiac mitochondria and be able to regulate ROS generation and MPTP opening [96].
MPTP, which has been reported to cause oxidative stress in the brains of mice, induced TFEB upregulation in the animals, whereas the antioxidants NAC and SS-31 significantly reduced TFEB expression (Figure 3(d)).
In monkeys exposed to MPTP 5-14 years before death and free from MPTP exposure for 3 years before death, biopsy data showed reactive microglia and extracellular melanin (McGeer et al.
Those experiments included transplants of dopamine-producing cells onto the brains of animals in which researchers had induced Parkinson-like symptoms with the chemical MPTP, and transplants of adult human adrenal cells onto the brains of patients with Parkinson's disease.
attention deficit hyperactivity disorder, schizophrenia, PD), experimental studies have repeatedly demonstrated protective effects of estrogen in various experimental models, including protection against the DA toxicity associated with the experimental compound MPTP as well as against methamphetamine-induced DA toxicity (Dluzen and McDermott 2002; Dluzen et al.
AEOL 11207 was tested for neuroprotection and oral bio-availability in the mouse MPTP model of Parkinson's disease.
The MPTP includes a comprehensive metro consists of 3 lines with a total length about 100 km and 70 stations .
Tipping points and endogenous determinants of nigrostriatal degeneration by MPTP.
This raises concern because exposure to other mitochondrialinhibiting drugs - such as rotenone and MPTP --is associated with increased risk for Parkinson's disease.
Neuroprotective effects of caffeine in MPTP model of Parkinson's disease: A(13)C NMR study.